Where American psychedelic research began — and where it is heading
A research-first educational resource for Boston and the Greater Boston metro. Harvard’s legacy. McLean Hospital’s present. Massachusetts legal context. Peer-reviewed findings — presented factually, without commercial framing.
Where American academic psychedelic research was born — Cambridge, Massachusetts
No American city has a deeper institutional history with academic psychedelic research than Boston. The foundational studies that shaped the modern literature were conducted not in California, not at a government facility — but at Harvard University and Boston University, in Cambridge and the Fenway.
“No American institution contributed more to the early academic literature on psilocybin than Harvard University — in Cambridge, Massachusetts.”
The Greater Boston metro is not simply a city where psychedelic research is being studied. It is the city where American institutional psychedelic research began. That sixty-year continuum — from Harvard’s original project to McLean’s current clinical trials — is unique to Boston in the American research landscape.
One city. One continuous legacy.
What neuroplasticity is — and why Boston researchers are studying it alongside psychedelic compounds
Neuroplasticity is the brain’s capacity to reorganize itself by forming new neural connections. This capacity continues throughout adult life. It is the foundational concept behind learning, behavioral change, and recovery from certain neurological conditions.
A growing body of peer-reviewed literature — published in journals including Neuron, JAMA Psychiatry, and Pharmacological Reviews — has examined whether and how certain psychedelic compounds interact with neuroplastic mechanisms. Boston-area institutions including McLean Hospital, MGH, and Harvard Medical School are active contributors to this literature.
This page presents the published findings neutrally, without clinical claims or personal-use guidance, for a community with exceptional depth of access to the primary research.
What Boston-area researchers are examining
No personal-use guidance.
No commerce.
The REBUS model: how researchers explain what psychedelic compounds do in the brain
REBUS — Relaxed Beliefs Under Psychedelics — published by Carhart-Harris and Friston in Pharmacological Reviews (2019). One of the most cited theoretical frameworks in the modern psychedelic research literature.
Your brain on a studied compound: what the published mechanism actually describes
A plain-English documentary explainer — 11 scenes, approximately 3 minutes. How psilocybin interacts with the brain at the molecular level, as described in peer-reviewed published literature.
SCENE 01
Researchers examining this compound describe a fundamental question in the literature: a quantity too small to produce perceptible effects — what is it actually doing inside the body?
SCENE 02
Published research documents that psilocybin itself is biologically inactive. An enzyme converts it into psilocin — the active form — a process documented across peer-reviewed pharmacology literature.
SCENE 03
Psilocin, the active metabolite, binds preferentially to the 5-HT2A serotonin receptor — a molecular interaction documented extensively in published neuroscience research.
SCENE 04
Published research notes that 5-HT2A is the same receptor family targeted by many mood-related pharmaceutical agents, though reached by a different molecular pathway.
SCENE 05
5-HT2A receptors are concentrated on the brain's Default Mode Network — the system researchers associate with self-referential thought, rumination, and the internal monologue.
SCENE 06
Academic literature documents that when the Default Mode Network is persistently overactive, it correlates with patterns of anxious and repetitive self-focused cognition. Published research examines how psilocin interacts with this network.
SCENE 07
Published research documents that psilocybin administration is associated with increases in BDNF — Brain-Derived Neurotrophic Factor — a protein that supports the formation of new neural connections.
SCENE 08
Neuroplasticity — the brain's capacity to form new connections — is the central theoretical framework in the published psychedelic research literature for understanding reported lasting effects.
SCENE 09
Published research acknowledges that the basic receptor mechanism is well established in the literature. Broader questions remain the subject of active academic investigation across major research institutions.
SCENE 10
The academic literature characterizes the science as theoretically plausible and the subject of ongoing peer-reviewed investigation at institutions including Johns Hopkins, Yale, Harvard, and McLean Hospital.
SCENE 11
This content summarizes published academic research. It is not medical advice. For adults 21 and over.
What the published literature reports
A neutral summary of published, peer-reviewed findings. All statistics describe outcomes observed in supervised research or clinical trial settings — not outcomes for any personal practice.
From 1960 to present — unbroken academic record
First formal US academic psilocybin research — Cambridge, Massachusetts
First double-blind psilocybin study in American academic history
Active Harvard-affiliated clinical research — most active East Coast site
Multiple companies with Boston-area presence in active clinical development programs
The city where it continues.
Psilocybin remains controlled in Massachusetts — with important local distinctions
Massachusetts has not enacted statewide psilocybin decriminalization. Psilocybin remains a Schedule I controlled substance under federal law and remains controlled under Massachusetts state law outside of approved research settings.
Several Massachusetts municipalities have independently adopted local enforcement-deprioritization resolutions. Cambridge and Somerville passed local resolutions in 2021. Northampton passed a similar resolution the same year. These are local enforcement-priority policies — they do not create a legal sales framework, do not override state law, and do not override federal Schedule I classification.
The city of Boston proper has not adopted a local enforcement-deprioritization resolution as of 2026. Residents of Beacon Hill, Back Bay, South End, Fenway, and other Boston neighborhoods are covered by Massachusetts state law and federal law.
Massachusetts legal landscape
Research exception
Psilocybin research at Boston-area institutions (McLean Hospital, MGH, Harvard Medical School) is conducted legally under DEA Schedule I research licenses. The clinical findings cited on this page were generated in those licensed research contexts.
Boston’s neighborhoods and the research ecosystem
The research literature and its legal context intersect differently across Greater Boston’s neighborhoods — from Harvard Square’s academic core to Somerville’s local deprioritization to the Longwood Medical Area’s active research cluster.
The academic ecosystem behind the published research
No metro area in the United States has a comparable concentration of research institutions contributing to the published psychedelic literature. The following institutions have published peer-reviewed findings or are affiliated with active research programs:
The research tradition is part of it.
Want to go deeper into the published research?
This educational resource covers the peer-reviewed findings, Massachusetts legal context, and Boston’s unique research legacy.
This page and all linked resources are educational only. No commerce, no personal-use guidance, no medical or legal advice.
Or send a message with questions about the research.
Questions about the research and legal status
Massachusetts’ legal context, Harvard’s research history, and the neuroscience of psilocybin — answered directly and accurately for a Greater Boston audience.
Contact the editorial team with research citation questions, corrections, or source suggestions.
Send a research question →Contact the editorial team
Submit a research citation question, editorial correction, or source suggestion.